Methylmalonic Acidemia (MMA) Market Size Projected To Reach 12.49 Billion By 2034 With A Cagr Of 5.8%

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Projected Growth of the Methylmalonic Acidemia (MMA) Market?
In recent times, the methylmalonic acidemia (MMA) market has been experiencing robust growth. It is forecasted that the market will escalate from $9.39 billion in 2024 to $9.97 billion in 2025, representing a compound annual growth rate (CAGR) of 6.2%. Factors contributing to growth in the past include surges in metabolic disorders and vitamin deficiencies, heightened healTH*Care spending, rising health consciousness, an uptick in genetic disorders, and increased demand from different end-user sectors.

Anticipations are high for robust expansion of the methylmalonic acidemia (MMA) market over the upcoming years, as it is projected to hit the $12.50 billion mark in 2029, progressing at a compound annual growth rate (CAGR) of 5.8%. The anticipated growth within the forecast period can be credited to factors such as escalating newborn screening initiatives, heightened awareness amongst medical professionals, advancements in gene therapy, increased funding in rare disease investigations, and a wider accessibility to specialized treatments. Identified as dominating trends within the forecast timeline are the evolution in gene-editing technologies, state-of-the-art diagnostic methods for early detection, improvements in enzyme replacement therapy, embracing precision medical strategies, and the uptake of newborn genetic screening programs.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22057

What Are the Different Methylmalonic Acidemia (MMA) Market Segments?
The methylmalonic acidemia (MMA) market covered in this report is segmented -

1) By Indication: Acidosis, Ke*tosis, Hyperammonemia, Hypoglycaemia, Hyperglycaemia, Neutropenia, Other Indications
2) By Disorder Type: Homocystinuria, Isolated Methylmalonic Acidurias, Combined methylmalonic Aciduria
3) By Distribution Channel: Hospitals, Pharmacies, Clinics, Other Distribution Channels

Subsegments:
1) By Acidosis: Metabolic Acidosis, Lactic Acidosis
2) By Ke*tosis: Starvation-Induced Ke*tosis, Diabetic Ke*toacidosis
3) By Hyperammonemia: Acute Hyperammonemia, Chronic Hyperammonemia
4) By Hypoglycemia: Fasting Hypoglycemia, Reactive Hypoglycemi
5) By Hyperglycemia: Transient Hyperglycemia, Persistent Hyperglycemia
6) By Neutropenia: Severe Neutropenia, Cyclic Neutropenia
7) By Other Indications: Failure to Thrive, Developmental Delays, Neurological Symptoms, Renal Dysfunction

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp

What Are the Primary Drivers Shaping the Methylmalonic Acidemia (MMA) Market?
A surge in metabolic disorders and vitamin deficiencies is projected to drive the methylmalonic acidemia (MMA) market in the future. Metabolic disorders involve a set of conditions that disturb the body's ability to process nutrients, generate energy, or manage chemical reactions at a cellular level. Vitamin deficiencies are a result of inadequate specific vitamins needed for normal body functions. The escalation in metabolic disorders and vitamin deficiencies can be attributed to poor diets, lack of physical activity, and heightened stress levels. Contemporary diets, rich in processed foods, sugars, and unhealthy fats, and inadequate in necessary nutrients, result in a lack of vitamins and minerals. Metabolic disorders and vitamin deficiencies, particularly the deficiency of vitamin B12, disrupt the metabolism of methylmalonyl-CoA leading to the accumulation of methylmalonic acid and worsening of methylmalonic acidemia (MMA). For example, as per the National Institutes of Health, a US-based government institution, the rates of vitamin B12 deficiency rose from 4.6% to 5.2% in November 2024, making a difference of an additional 507 cases between the third and fourth quarters of 2023. Hence, the upward trend in metabolic disorders and vitamin deficiencies fuels the growth of the methylmalonic acidemia (MMA) market.

Which Companies Are Leading in the Methylmalonic Acidemia (MMA) Market?
Major companies operating in the methylmalonic acidemia (MMA) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.

What Are the Major Trends Shaping the Methylmalonic Acidemia (MMA) Market?
Prominent players in the methylmalonic acidemia (MMA) market are concentrating their efforts on the invention of revolutionary solutions, for example, therapies based on mRNA, in order to enhance treatment results by attacking the genetic roots of MMA and boosting enzyme activity to minimize the build-up of harmful metabolites in patients. Therapies based on messenger RNA, which direct cells to create specific proteins, can aid in preventing or managing diseases like genetic disorders or infections. For example, in June 2024, Moderna, Inc., a pharmaceutical and biotechnology firm from the US, secured an approval from the U.S. Food and Drug Administration (FDA) to incorporate mRNA-3705 into the START trial initiative, making a significant contribution to the progress of treatments for rare ailments. mRNA-3705, an experimental treatment for MMA caused by MUT scarcity, aims to replenish the absent enzyme via mRNA technology. This therapy takes advantage of Moderna's proprietary lipid nanoparticle (LNP) system, also employed in the mRNA-3927 scheme for propionic acidemia. The FDA has provided mRNA-3705 with orphan drug, fast track, and rare pediatric disease status, thus facilitating its swift development and clinical advancement.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

What Are the Top Revenue-Generating Geographies in the Methylmalonic Acidemia (MMA) Market?
North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (MMA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Methylmalonic Acidemia (MMA) Market?
2. What is the CAGR expected in the Methylmalonic Acidemia (MMA) Market?
3. What Are the Key Innovations Transforming the Methylmalonic Acidemia (MMA) Industry?
4. Which Region Is Leading the Methylmalonic Acidemia (MMA) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.